Ronald Chow1, Crystal Valdez2, Natalie Chow2, Daniel Zhang2, James Im2, Emily Sodhi2, Michael Lock2. 1. London Regional Cancer Program, London Health Sciences Centre, University of Western Ontario, 800 Commissioners Road East, London, ON, N6A 5W9, Canada. rchow48@uwo.ca. 2. London Regional Cancer Program, London Health Sciences Centre, University of Western Ontario, 800 Commissioners Road East, London, ON, N6A 5W9, Canada.
Abstract
INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) is a burdensome adverse event frequently associated with chemotherapy treatment of cancer. Evidence suggests that cannabinoid CB2 receptors are present in brainstem neurons, and thus, there may exist a role for cannabinoids to counter CINV. The aim of this paper is to conduct a systematic review and meta-analysis of the efficacy and safety of oral cannabinoids compared with other treatments as documented in randomized controlled trials (RCTs). METHODS: A literature search was conducted using Ovid MEDLINE up until December 31, 2018; Embase Classic and Embase up until 2018 week 53; and Cochrane Central Register of Controlled Trials up until November 2018. Study data were extracted and included in this meta-analysis if they reported on at least one of the following efficacy endpoints: no nausea and no vomiting, no nausea, and no vomiting. The Mantel-Haenszel method and random effects analysis model were used, to generate odds ratio (OR) and accompanying 95% confidence intervals (CI). RESULTS: In the setting of prophylactic treatment against both nausea and vomiting, oral cannabinoid was more efficacious than placebo or other studied antiemetic treatments. When controlling for vomiting, oral cannabinoid was equally as efficacious as others. Against nausea, oral cannabinoid was equally as effective as other treatments. A greater percentage of patients administered oral cannabinoid for CINV experienced dysphoria, euphoria, and sedation. CONCLUSION: Although there exists some evidence suggesting that oral cannabinoids may have a role in controlling for emesis from a neurophysiological perspective, these conclusions are currently not mirrored in the published RCTs to date. However, there exists only a limited number of RCTs, comparisons with older treatment regimens and a lack of standard reporting practice across published literature. Further RCTs should investigate the efficacy and safety of oral cannabinoids, to secure a better picture of the efficacy of oral cannabinoids against CINV.
INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) is a burdensome adverse event frequently associated with chemotherapy treatment of cancer. Evidence suggests that cannabinoid CB2 receptors are present in brainstem neurons, and thus, there may exist a role for cannabinoids to counter CINV. The aim of this paper is to conduct a systematic review and meta-analysis of the efficacy and safety of oral cannabinoids compared with other treatments as documented in randomized controlled trials (RCTs). METHODS: A literature search was conducted using Ovid MEDLINE up until December 31, 2018; Embase Classic and Embase up until 2018 week 53; and Cochrane Central Register of Controlled Trials up until November 2018. Study data were extracted and included in this meta-analysis if they reported on at least one of the following efficacy endpoints: no nausea and no vomiting, no nausea, and no vomiting. The Mantel-Haenszel method and random effects analysis model were used, to generate odds ratio (OR) and accompanying 95% confidence intervals (CI). RESULTS: In the setting of prophylactic treatment against both nausea and vomiting, oral cannabinoid was more efficacious than placebo or other studied antiemetic treatments. When controlling for vomiting, oral cannabinoid was equally as efficacious as others. Against nausea, oral cannabinoid was equally as effective as other treatments. A greater percentage of patients administered oral cannabinoid for CINV experienced dysphoria, euphoria, and sedation. CONCLUSION: Although there exists some evidence suggesting that oral cannabinoids may have a role in controlling for emesis from a neurophysiological perspective, these conclusions are currently not mirrored in the published RCTs to date. However, there exists only a limited number of RCTs, comparisons with older treatment regimens and a lack of standard reporting practice across published literature. Further RCTs should investigate the efficacy and safety of oral cannabinoids, to secure a better picture of the efficacy of oral cannabinoids against CINV.
Entities:
Keywords:
Cannabinoid; Chemotherapy-induced nausea and vomiting; Dronabinol; Efficacy; Nabilone; Safety
Authors: Marja D Van Sickle; Marnie Duncan; Philip J Kingsley; Abdeslam Mouihate; Paolo Urbani; Ken Mackie; Nephi Stella; Alexandros Makriyannis; Daniele Piomelli; Joseph S Davison; Lawrence J Marnett; Vincenzo Di Marzo; Quentin J Pittman; Kamala D Patel; Keith A Sharkey Journal: Science Date: 2005-10-14 Impact factor: 47.728
Authors: Ronald Chow; David G Warr; Rudolph M Navari; May Tsao; Marko Popovic; Leonard Chiu; Milica Milakovic; Henry Lam; Carlo DeAngelis Journal: Support Care Cancer Date: 2018-05-23 Impact factor: 3.603
Authors: Richard J Gralla; Ronald de Wit; Jorn Herrstedt; Alexandra D Carides; Juliana Ianus; Julie Guoguang-Ma; Judith K Evans; Kevin J Horgan Journal: Cancer Date: 2005-08-15 Impact factor: 6.860
Authors: F P Bymaster; D O Calligaro; J F Falcone; R D Marsh; N A Moore; N C Tye; P Seeman; D T Wong Journal: Neuropsychopharmacology Date: 1996-02 Impact factor: 7.853
Authors: D Cunningham; C J Bradley; G J Forrest; A W Hutcheon; L Adams; M Sneddon; M Harding; D J Kerr; M Soukop; S B Kaye Journal: Eur J Cancer Clin Oncol Date: 1988-04
Authors: Ronald Chow; Leonard Chiu; Rudolph Navari; Steven Passik; Nicholas Chiu; Marko Popovic; Henry Lam; Mark Pasetka; Edward Chow; Carlo DeAngelis Journal: Support Care Cancer Date: 2015-11-04 Impact factor: 3.603
Authors: S Frytak; C G Moertel; J R O'Fallon; J Rubin; E T Creagan; M J O'Connell; A J Schutt; N W Schwartau Journal: Ann Intern Med Date: 1979-12 Impact factor: 25.391
Authors: Franziska Jahn; Bernhard Wörmann; Juliane Brandt; Annette Freidank; Petra Feyer; Karin Jordan Journal: Dtsch Arztebl Int Date: 2022-05-27 Impact factor: 8.251
Authors: Ronald Chow; Jørn Herrstedt; Matti Aapro; Leonard Chiu; Henry Lam; Elizabeth Prsic; Michael Lock; Carlo DeAngelis; Rudolph M Navari Journal: Support Care Cancer Date: 2021-01-13 Impact factor: 3.359
Authors: Michael J Stoner; Ann Dietrich; Samuel Hiu-Fung Lam; Jessica J Wall; Carmen Sulton; Emily Rose Journal: J Am Coll Emerg Physicians Open Date: 2022-07-05